BioTech IP Review

Methods of Using Cyclic Peptides That Bind to TNFR1

Patent Title: Methods of Using Cyclic Peptides That Bind to TNFR1
Publication Number: WO/2025/166198
Application Number: PCT/US2025/014081
Filing Date: January 31, 2025
Publication Date: August 07, 2025
Applicant: Merck Sharp & Dohme LLC (Rahway, NJ, USA)

What This Patent Covers

This international patent application relates to cyclic peptide molecules that specifically bind to the Tumor Necrosis Factor Receptor 1 (TNFR1) and methods of using them:

Target & Mechanism

  • The invention focuses on cyclic peptides engineered to bind TNFR1, a key receptor in the TNF (tumor necrosis factor) signaling pathway. This pathway regulates inflammation, immune responses, and apoptosis (cell death).

Therapeutic Use

  • Such TNFR1‑binding peptides can be used to modulate TNF signaling. By blocking or altering TNFR1 activity, these peptides may reduce inflammation and immune‑mediated damage, making them potentially useful in treating autoimmune disorders, inflammatory diseases, and certain cancers.

Methods of Administration

  • The application outlines methods of treatment using these cyclic peptides in patients with diseases where TNF‑driven inflammation is pathogenic, which could include conditions like rheumatoid arthritis, inflammatory bowel disease, psoriasis, and others.

Structural Innovation

  • Cyclic peptides often show enhanced stability, affinity, and selectivity compared to linear peptides or small molecules. This can translate into more effective and durable therapeutic responses with potentially fewer side effects.

Why This Patent Is Important

1) Aligns with High‑Revenue Therapeutic Areas
Merck’s blockbuster cancer immunotherapy Keytruda generated nearly $30 billion in sales in 2025, illustrating the company’s strength in immunology and oncology; innovations in immune modulation help sustain its pipeline as existing patents approach expiration.

2) Broad Clinical Potential
TNFR1 is implicated in many inflammatory and immune‑mediated diseases. A new class of TNFR1‑targeting therapeutics could open blockbuster markets beyond traditional small molecules and biologics.

3) Strategic R&D Positioning
Owning IP around cyclic peptides that bind a major immune receptor gives Merck a platform for differentiated therapies — potentially combining immunomodulation with precision targeting for improved safety and efficacy.

Leave a comment